Bolivia is showing signs of returning to normalcy after President Paz declared a state of emergency to end a 50-day social crisis. The Legislative Assembly approved the decree, aiming to restore transit and supply essential goods. Agreements were reached in Santa Cruz, and a La Paz federation paused protests, though demands remain.
The Indian government has banned 16 Fixed Dose Combinations (FDCs) of drugs, citing a lack of therapeutic justification and potential risks outweighing benefits. The prohibition, effective immediately, covers various categories including dermatological, analgesic, antispasmodic, and antibiotic formulations.
CVS is transitioning its over-the-counter medications to aluminum bottles, moving away from traditional plastic packaging. This change aims to improve sustainability and product stability, with initial conversions focusing on value-sized allergy and pain medications.
The U.S. has launched an investigation into Germany's pharma policies, citing "persistent underpayment" for medicines as Germany seeks to control rising healthcare costs. U.S. Trade Representative Jamieson Greer expressed concern over proposed legislation to reduce drug spending, calling it a "serious step backwards."
Zealand Pharma's stock dropped significantly due to high dropout rates for its weight loss drug survodutide. While survodutide's peak sales forecasts were cut, investors are now focusing on the company's amylin-based drug, petrelintide, as a potential future growth driver.
Zealand Pharma's stock dropped significantly due to high dropout rates for its weight loss drug survodutide. Investors are now focusing on its amylin-based drug, petrelintide, as the next potential growth driver, despite competition and previous efficacy concerns.
The US has initiated a trade probe into Germany's drug pricing policies, suspecting systematic underpayment for innovative medicines. Washington claims US patients bear a disproportionate R&D cost burden and warns of potential trade measures, including tariffs, if no resolution is reached.
Zealand Pharma's stock dropped significantly after survodutide showed high patient dropout rates. Investors are now focusing on its amylin-based drug, petrelintide, as a potential future driver, despite competition and previous efficacy concerns.
CVS is transitioning its over-the-counter (OTC) medications to aluminum bottles, moving away from traditional plastic packaging. This change aims to improve sustainability and practicality, with initial rollout on value-sized allergy and pain medications. Pricing remains unaffected, and customer response will determine wider adoption.
President Vladimir Putin suggests Russia will increase exports of high-value products like fertilizers and medicines to ASEAN, alongside continued food and energy supplies.
UK health leaders warn of severe NHS medicine shortages, including painkillers and HRT, impacting patient safety and forcing some to skip meals. Supply chain issues, manufacturing disruptions, and budget constraints are cited as causes.
India has removed cough syrups from Schedule K of the Drugs Rules, 1945, ending a decades-old exemption that allowed their sale without a doctor's prescription in villages under 1,000 population. This change aims to enhance regulatory oversight and traceability, following concerns over contaminated syrups linked to child deaths.
India's Union health ministry has amended drug regulations, making a doctor's prescription mandatory for purchasing syrup-based medicines, including cough syrups. The change, effective June 9, removes 'syrups' from Schedule K, ending over-the-counter sales and strengthening regulatory oversight.
India's Ministry of Health and Family Welfare now requires a doctor's prescription to buy cough syrups and other syrup medicines, ending over-the-counter sales. This move aims to prevent misuse, recreational drug use, and accidental poisoning, especially among adolescents and young adults, and addresses a history of contaminated Indian-made medicines causing child deaths globally.
Revolution Medicines' experimental drug, daraxonrasib, has shown unprecedented success in treating advanced pancreatic cancer, doubling patient survival rates and significantly reducing the risk of death by 60% compared to standard chemotherapy. The drug, a first-in-class RAS(ON) inhibitor, targets specific RAS gene mutations and demonstrated a remarkable improvement in tumor shrinkage and patient quality of life, with a much lower incidence of severe side effects. The FDA has granted it expanded access and speedy review.
The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.
India's Competition Commission (CCI) has dismissed allegations against 12 Delhi hospitals for inflating healthcare charges, stating price regulation is the government's domain. The ruling, which follows a decade-long investigation, is criticized for potentially overlooking consumer protection mandates in the $372-billion healthcare industry.
Over a third of essential medicines are out of stock, endangering over 4,000 cancer patients and thousands of kidney dialysis patients.
AstraZeneca CEO Pascal Soriot discusses how AI enhances productivity in drug discovery and development, enabling smarter design, side effect reduction, and improved trial success prediction.
Russia and Cuba will sign a memorandum today for the joint development of cancer vaccines. Deputy Prime Minister Dmitry Chernyshenko announced this at the St. Petersburg International Economic Forum (SPIEF), where Russia also noted interest from 90 companies in supplying agricultural products to Cuba.
European patients face increasing delays in accessing new medicines, with average wait times reaching 597 days. Despite strong scientific innovation, fragmented national systems hinder timely access post-approval. An 'Access from Day 1' approach is proposed to streamline pathways, ensuring innovation reaches patients faster and more equitably.
Global antibiotic use in livestock is projected to increase by 30% by 2040 without government intervention, potentially leading to disastrous impacts on human resistance to medicines. The UN's FAO report highlights the rise of superbugs and calls for better regulation.
South Korea's Ministry of Food and Drug Safety has newly designated three essential medicines, including two cancer injection drugs (Dacarbazine and Doxorubicin) and Cisatracurium injection, as national essential medicines. This brings the total number of national essential medicines to 491, aiming to ensure stable supply for patients.
Um novo medicamento, daraxonrasib, dobrou a sobrevida mediana de pacientes com câncer de pâncreas metastático em estudo de fase 3, reduzindo o risco de morte em 60% e apresentando baixa toxicidade. Os resultados foram apresentados na ASCO e devem levar à aprovação regulatória nos EUA.
